The suspension by India took place after a meeting by the European Union, to consider giving member states greater scope to block vaccines being exported outside the bloc, much of which is struggling to bring infections down and ramp up immunisation campaigns.
The EU has accused the AstraZeneca drugmaker of over-selling its vaccine and unfairly favouring Britain, – a charge denied by the company.
The duration of the suspension is still unknown, but it is suspected to cause a delay in the delivery of the nation’s second batch of the COVID vaccine supplies, which was initially expected to arrive by the end of March and early April, an additional 42 million doses.
Other African countries are likely to also be affected by the suspension.
It was gathered that the suspension would apply to all vaccines including the AstraZeneca shot on which the EU had originally been relying to meet a goal of inoculating 70 percent of its adult population.